IgA nephropathy
JV Donadio, JP Grande - New England Journal of Medicine, 2002 - Mass Medical Soc
JV Donadio, JP Grande
New England Journal of Medicine, 2002•Mass Medical SocIgA nephropathy is the most common form of primary glomerulonephritis in the world and is
also the most common cause of end-stage renal disease in patients with primary
glomerulopathy. This article discusses current views on the pathogenesis, pathophysiology,
clinical course, and treatment of this important glomerular disease. Although clinical trials
have suggested that therapies such as glucocorticoids, n–3 fatty acids, and angiotensin-
converting–enzyme inhibitors are efficacious, more definitive treatment is being sought.
also the most common cause of end-stage renal disease in patients with primary
glomerulopathy. This article discusses current views on the pathogenesis, pathophysiology,
clinical course, and treatment of this important glomerular disease. Although clinical trials
have suggested that therapies such as glucocorticoids, n–3 fatty acids, and angiotensin-
converting–enzyme inhibitors are efficacious, more definitive treatment is being sought.
IgA nephropathy is the most common form of primary glomerulonephritis in the world and is also the most common cause of end-stage renal disease in patients with primary glomerulopathy. This article discusses current views on the pathogenesis, pathophysiology, clinical course, and treatment of this important glomerular disease. Although clinical trials have suggested that therapies such as glucocorticoids, n–3 fatty acids, and angiotensin-converting–enzyme inhibitors are efficacious, more definitive treatment is being sought.
The New England Journal Of Medicine